CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer by Jung-Min Lee et al.
ORIGINAL RESEARCH
published: 01 June 2015
doi: 10.3389/fonc.2015.00123
Edited by:
Viive Maarika Howell,
University of Sydney, Australia
Reviewed by:
James M. Ford,
Stanford University School of
Medicine, USA
Connie Irene Diakos,
University of Sydney, Australia
*Correspondence:
Jung-Min Lee,
10 Center Drive MSC1906, Building
10, Room 12N/226, Bethesda, MD
20892-1906, USA
leej6@mail.nih.gov
Specialty section:
This article was submitted to
Women’s Cancer, a section of the
journal Frontiers in Oncology
Received: 25 March 2015
Accepted: 17 May 2015
Published: 01 June 2015
Citation:
Lee J-M, Trepel JB, Choyke P, Cao L,
Sissung T, Houston N, Yu M,
Figg WD, Turkbey IB, Steinberg SM,
Lee M-J, Ivy SP, Liu JF, Matulonis UA
and Kohn EC (2015) CECs and IL-8
have prognostic and predictive utility
in patients with recurrent
platinum-sensitive ovarian cancer:
biomarker correlates from the
randomized phase-2 trial of olaparib
and cediranib compared with olaparib
in recurrent platinum-sensitive ovarian
cancer.
Front. Oncol. 5:123.
doi: 10.3389/fonc.2015.00123
CECs and IL-8 have prognostic and
predictive utility in patients with
recurrent platinum-sensitive ovarian
cancer: biomarker correlates from
the randomized phase-2 trial of
olaparib and cediranib compared
with olaparib in recurrent
platinum-sensitive ovarian cancer
Jung-Min Lee1*, Jane B. Trepel1, Peter Choyke1, Liang Cao1, Tristan Sissung1,
Nicole Houston1, Minshu Yu1, William D. Figg1, Ismail Baris Turkbey 1, Seth M. Steinberg1,
Min-Jung Lee1, S. Percy Ivy 2, Joyce F. Liu3, Ursula A. Matulonis3 and Elise C. Kohn1
1 Center for Cancer Research, Bethesda, MD, USA, 2 Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda,
MD, USA, 3 Dana-Farber Cancer Institute, Boston, MA, USA
Objective: Olaparib (O), a polyADPribose polymerase (PARP) inhibitor, and cediranib (C),
a VEGF receptor (VEGFR)1–3 inhibitor together had greater activity than O alone in women
with recurrent platinum-sensitive ovarian cancer (OvCa). The objective of this study is to
identify potential lead biomarker candidates for response to O+C in the setting of a
multi-institutional phase II study of O with and without C in recurrent platinum-sensitive
OvCa.
Methods: A self-selected group of patients participated in a prospectively planned
exploratory biomarker substudy of the randomized phase II study of O versus O+C.
Whole blood for peripheral blood mononuclear cell (PBMC) and plasma isolation was
collected prior to and on day 3 of treatment. Quantitation of circulating endothelial cells
(CEC), IL-6, IL-8, VEGF, and soluble VEGFR-2 plasma concentrations, and polyADPri-
bose (PAR) incorporation were performed. Single nucleotide polymorphism analysis of
XRCC1 280H, R194W, and Q399R was done. Dynamic contrast-enhanced-magnetic
resonance imaging (DCE-MRI) was performed at baseline and day 3 of treatment.
Parameter changes were compared between the two arms using an exact Wilcoxon rank
sum test. Kaplan–Meier and log-rank tests were used to examine survival outcome.
Results: Thirteen patients elected to participate in the translational substudy, seven
patients on O and six patients on O+C. Patients on O+C had a greater decrease
in IL-8 concentration and larger CEC fold increase compared with those on O alone
(p=0.026, p=0.032). The fold increase in CEC on day 3 was associated with dura-
tion of progression-free survival (PFS) (R2=0.77, 95% CI 0.55–0.97, p<0.001). IL-8
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post-pretreatment changes correlate with PFS (p=0.028). XRCC1 DNA polymorphisms
were not related to PFS. All patients had reduction in PAR incorporation, and all except
one had reduction in vascular flow on DCE-MRI.
Conclusion: Our exploratory correlative studies indicate that CEC and IL-8 changes may
be predictive for response to O+C and prognostic in recurrent platinum-sensitive OvCa,
requiring prospective validation.
Keywords: CEC, IL-8, biomarkers, olaparib, cediranib, ovarian cancer
Introduction
Ovarian cancer (OvCa) accounts for the majority of gynecologic
cancer deaths in the United States (1). Most women with OvCa
present with advanced disease, and recurrence is nearly universal
leading to incurable disease and limited treatment options (2, 3).
The optimal way to incorporate new agents into OvCa treatment
and when to initiate these agents remains a question. Women
whose disease progresses more than 6months after exposure to
platinum agents tend to respond better to subsequent interven-
tions than those with platinum-resistant or refractory disease,
making them another important cohort in whom to investi-
gate new directions. OvCa is an angiogenic cancer and activity
has been shown with inhibitors of the VEGF/VEGF receptor
(VEGFR) axis (2, 4–8). The recognition that OvCa may be driven
by disordered DNA damage repair led to the development and
recent approval of polyADPribose polymerase (PARP) inhibition
for therapeutic benefit. Therefore, inhibition of both DNA dam-
age repair and angiogenesis pathways would be an important
direction to be examined.
Preclinical studies demonstrate potential interaction between
angiogenesis andDNAdamage repair pathways. γH2AX, amarker
of the DNA damage repair response, is necessary for endothelial
cell proliferation under hypoxia and hypoxia-driven neovascu-
larization in vivo (9). It has been shown that hypoxia leads to
downregulation of BRCA1 andRAD51,making hypoxic lung can-
cer cells more sensitive to PARP inhibitors (PARPi) (10). PARP1
inhibition also increases VEGFR-2 phosphorylation and subse-
quent activation of endothelial cell survival in human umbilical
vein endothelial cells, an effect, which was reversed by a VEGFR-2
inhibitor (11). Our preliminary work showed that the combina-
tion of olaparib and cediranib inhibited invasion of OvCa cells, in
amore than additive fashion. Invasion was significantly decreased
in pretreated OvCa cell lines, CAOV3 and OVCAR8, exposed to
concentrations attainable in patients, cediranib 50 nM or olaparib
10µM, or the combination (p< 0.0001 for all treatments). Addi-
tionally, olaparib and cediranib inhibited microvascular endothe-
lial cell tube formation on Matrigel at concentrations well below
those clinically attainable in patients. Cumulative tube length was
significantly reduced when endothelial cells were exposed to cedi-
ranib 5 nM or olaparib 100 nM (all p< 0.05). The combination
of olaparib and cediranib resulted in greater inhibition of tube
formation thanmonotherapy (p< 0.0001, Kim et al., unpublished
data). These preclinical data suggest new strategies for novel com-
bination therapies in recurrent OvCa.We hypothesized that intro-
duction of angiogenesis inhibitors and PARPi will have activity
and examination of the biology should lead to potential predictive
biomarkers (7, 12, 13).
PolyADPribose polymerase inhibitors are a novel class of
drugs designed to compete with NAD+ for the substrate bind-
ing site of PARP, preventing DNA single strand break repair
process through the base excision repair pathway (14). Another
mechanism of PARPi includes trapping of PARP1 and PARP2
while in complex with damaged DNA, resulting in cytotoxic
consequences (15). Trapped PARP prevents its availability for
repair function and secondarily causes replication and tran-
scription fork blockade, and subsequent DNA breakage. Ola-
parib, a PARPi, was approved recently by the US Food and
Drug Administration for use in advanced OvCa patients bear-
ing deleterious germline BRCA1 and BRCA2 mutations (gBR-
CAm); clinical activity has also been reported in sporadic OvCa
(14, 16). Cediranib is a small-molecule tyrosine kinase inhibitor
of VEGFR1–3 and c-kit with modest single agent activity in
recurrent OvCa (8, 17). In the ICON 6 study, cediranib com-
bined with platinum and paclitaxel standard chemotherapy fol-
lowed by maintenance cediranib treatment significantly pro-
longed progression-free survival (PFS) and overall survival (OS)
when administered to women with first recurrence of platinum-
sensitive OvCa (17).
We recently reported a randomized phase-2 multi-institutional
study of olaparib capsules with or without cediranib for recurrent
platinum-sensitive OvCa, showing the combination improved
PFS (17.7 versus 9months, p= 0.005) and response rate (80
versus 48%, p= 0.002) (13). Prospectively planned exploratory
biomarker endpoints were included. The aim of this translational
study is to identify potential predictive biomarker candidates for
olaparib and cediranib by assessment of vascular and DNA repair
endpoints within the multi-institutional phase 2 study of olaparib
and cediranib.
Patients and Methods
Patients
The randomized study with the internal translational substudy
was approved by the institutional review boards of the partic-
ipating sites, and written informed consent was obtained from
participating patients; clinical study details including drug admin-
istration, safety, adverse events, and tumor response have been
reported and the schema for treatment is shown in Figure 1
(13). The patients who participated in the translational sub-
studies underwent dynamic contrast-enhanced-magnetic reso-
nance imaging (DCE)-MRI and blood collection prior to and
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FIGURE 1 | Treatment schema and correlative studies. Peripheral blood
mononuclear cell (PBMC), whole blood DNA, and plasma samples were
collected prior to initiation of the study drug(s), and all patients underwent
DCE-MRI imaging. Follow-up sampling was done on day 3 of treatment.
on day 3 of treatment. Study treatment, imaging, and blood col-
lection occurred at the Center for Cancer Research, NCI after
which the patients continued care at their primary investiga-
tional site.
Quantitation of Circulating Endothelial Cells and
Circulating Endothelial Progenitor Cells
Blood was collected in citrated CPT cell preparation tubes (BD
Vacutainer, Franklin Lakes, NJ, USA). PBMCs were isolated,
aliquoted, and viably frozen within 2 h of collection, and stored
at  80°C until use. Circulating endothelial cells (CEC) and cir-
culating endothelial progenitor cells (CEP) analyses were per-
formed using an MACSQuant flow cytometer (Miltenyi Biotec,
Bergisch Gladbach, Germany); a minimum of 1 105 cells were
acquired for each analysis. CECs were defined as negative for
the hematopoietic marker CD45 (leukocyte common antigen),
positive for the endothelial markers CD31 and CD146, and
negative for the progenitor marker CD133. CEPs were defined
as the CD45-/CD31+/CD146-/CD133+ population (18, 19).
Viability was defined by the absence of 7-aminoactinomycin
D (7-AAD) staining, and analysis was restricted to nucleated
cells by gating on Hoechst 33342-positive cells (20, 21). Data
were analyzed using FlowJo software (FlowJo LLC, Ashland,
OR, USA).
Cytokine Analysis
Plasma samples were collected in K2EDTA tubes (BDVacutainer)
and were processed within 2 h of collection. After centrifugation,
the samples were aliquoted, immediately frozen, and stored in liq-
uid nitrogen until use. Quantitative analysis of circulating plasma
VEGF, IL-6, IL-8, and soluble VEGFR-2 were performed using
analytically validated custom V-PLEX assay plates on an elec-
trochemiluminescence platform according to the manufacturer’s
instructions (Meso Scale Discovery, Gaithersburg, MD, USA)
(22). The concentrations of the cytokines were determined with
recombinant standards and expressed as picograms per milliliter,
as reported (23).
Measurements of PAR Incorporation, and
Isolation of DNA for Single Nucleotide
Polymorphism Analysis
Peripheral blood mononuclear cell DNA PARylation was mea-
sured using a commercial immunoassay according to the man-
ufacturer’s instructions (Trevigen, Gaithersburg, MD, USA) (24).
PBMC DNA was isolated for polymorphism analysis of XRCC1
280H, R194W, and Q399R using a commercial DNA purification
kit (Qiagen, Germantown, MD, USA), as reported (25).
DCE-MRI Functional Imaging
Dynamic contrast-enhanced-magnetic resonance imaging (DCE-
MRI) was performed to assess changes in vascular permeabil-
ity (Ktrans) and perfusion (Kep) (26). MRI data were analyzed
using a two-compartment model based on the general kinetic
(GKM) Kety model using commercial software (iCAD, Nashua,
NH, USA) as reported (27, 28). The GKM model analysis was
done with an Interactive Data Language-based (Research Sys-
tems Inc.) research tool (Cine Tool; GE Healthcare). Manual
region-of-interest measurements were obtained from each slice
of the target lesion. The GKM model produces three param-
eters: Kep, the reverse contrast transfer rate; Ktrans, the for-
ward contrast transfer rate; and Ve the extravascular fraction.
Baseline and day 3 of treatment Kep, Ktrans, and Ve values
were obtained.
Statistical Analysis
Parameter changes were compared between the two arms using an
exactWilcoxon rank sum test. The probability of PFS as a function
of time was estimated using the Kaplan–Meier method, with a
log-rank test to determine the significance of the differences. The
cut-off date for PFS and endpoint analysis of this subset wasMarch
31, 2014 consistent with the original study. All p-values are two-
tailed and reported without adjustment for multiple comparisons
due to the small substudy cohort.
Results
Patients
This substudy reports on 13 self-selected participants of themulti-
institutional randomized phase-2 study of recurrent platinum-
sensitive OvCa patients who were treated with olaparib capsules
(200mg twice a day) and cediranib (30mg daily) or olaparib
capsules alone (400mg twice a day) until disease progression (13).
Participating patient details are shown in Table 1, demonstrating
their representation of the full patient cohort in terms of age,
treatment arm distribution, and clinical outcome. Not all patients
could undergo imaging within the required time frame; Table 1
also includes the number and distribution of patients within each
of the substudy elements.
Quantitation of CEC and CEP
It has been reported that inhibition of angiogenesis induces a
feedback response with induction of angiogenic precursors (29–
31). Patients receiving both agents had a median 3.5-fold increase
in CEC compared to 0.7 for patients on single agent olaparib
(p= 0.032, Figure 2A). CEC fold increase pretreatment to day
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3 was associated with time to progression or follow-up with-
out progression when viewed on a patient-by-patient basis using
available follow-up data (R2= 0.77, 95% CI 0.55–0.97, p< 0.001;
Figure 2B). Baseline values of CEC and CEP were not associated
with PFS. CEP fold change was not significantly different between
the two arms.
Cytokine Analysis
Circulating cytokines have been proposed as potential biomarkers
of response to anti-angiogenics (32, 33). Our findings showed that
greater decreases in circulating IL-8 concentrations in patients
treated with olaparib and cediranib than with olaparib alone
TABLE 1 | Clinical characteristics (n= 13).
Olaparib Olaparib+cediranib
7 patients 6 patients
Age: median 53 (range 32–70) 53 (32–61) 57 (53–70)
Number of prior lines of therapy 1: 6 patients 1: 3 patients
2: 1 patients 2: 2 patients
3: 1 patients
Response rate 57% 83%
Best response PR: 4 PR: 5
SD >4months: 3 SD >4months: 1
PFS*, median 11.2months
(3.6–16.8)
13.8months
(7.5–22.2+)
BRCA1 or BRCA2 mutational
status
Mutated: 4 – or
unknown: 3
Mutated: 3 – or
unknown: 3
Paired correlative studies
Cytokinea 6 patients 6 patients
PAR incorporationb 6 patients 5 patients
CEC/CEPc 5 patients 5 patients
DCE-MRId 4 patients 6 patients
*p=0.60 for overall comparison, eight PFS events were observed, four patients on each
arm at the time of data cut-off (March 31, 2014).
aCytokine samples from one patient were missing.
bTwo patients had no optimal viable cells from the frozen samples for PAR analysis.
cThree patients had no optimal viable cells from the frozen samples for CEC/CEP analysis.
dThree patients were unable to tolerate DCE-MRIs.
(p= 0.026, Figure 3A). The median IL-8 difference with the com-
bination of olaparib and cediranib was  0.25. The patients with
greater decrease than median IL-8 difference was associated with
longer PFS (p= 0.028, Figure 3B). Median values of pretreat-
ment IL-8 concentration were not significantly different between
the two arms. Pretreatment values of other cytokines including
circulating plasma VEGF, soluble VEGFR-2, and IL-6 examined
did not correlate with PFS and was not different between two
arms. Values of other cytokines did not significantly change after
treatment in either arm.
Measurements of PAR Incorporation and
Polymorphism Analysis
PolyADPribose polymerase inhibitors activity was measured by
polyADPribose (PAR) incorporation into PBMC DNA. Reduc-
tion in PBMC PAR incorporation with treatment was observed
in both arms, indicating the lower dose of olaparib results in
full PAR inhibition and that addition of cediranib does not
diminish that olaparib function (Figure 4). We also examined
whether XRCC1 DNA polymorphisms correlate with clinical
response to PARPi and no significant associations with PFS
were observed.
Dynamic Contrast-Enhanced-Magnetic
Resonance Imaging
Permeability and perfusion calculations by DCE-MRI have been
used to characterize tumor vasculature changes in response to
the VEGF/VEGFR axis inhibitors (34). In this study, all patients
except one had a reduction with treatment in Ktrans and Kep inde-
pendent of treatment arm; increase of Kep on day 3 of treatment
in one patient was likely due to suboptimal contrast injection
timing (Figures 5A,C). No significant differences were observed
between the two treatment arms (Figures 5B,D). All patients had
at least stable disease at the first Response Evaluation Criteria in
Solid Tumors (RECIST) evaluation after two cycles of treatment,
indicating potential benefit but no correlation with the duration
of response.
FIGURE 2 | Circulating endothelial cells (CEC) and circulating
endothelial progenitor cells (CEP). (A) Patients receiving
olaparib/cediranib had a larger fold increase in CEC compared to olaparib
alone during treatment (p= 0.032). (B) The fold increase in CEC on day 3
was associated with PFS duration in all patients (R2= 0.77, 95% CI
0.55–0.97, p<0.001) when reporting values on a patient-by-patient
basis. The open dots represent patients whose times at risk were
censored on the date of their last contact and were last reported alive and
progression-free. This observed pattern may not retain the linear
relationship as time passes.
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FIGURE 3 | Proangiogenic cytokines. (A) Patients on olaparib/
cediranib had a greater change in circulating IL-8 concentration with
treatment than patients on olaparib alone (p= 0.026). (B) Patients with
greater IL-8 change [below the median IL-8 difference ( 0.25)] was
associated with longer PFS (p= 0.028). The 6-month PFS probability
for the six patients with changes above the median was 83.3% (95% CI
43.6–97.0), while for the group with the changes below the median, it
was 100% (95% CI 54.1–100). At 12months, the respective
probabilities of PFS were 20.8% (95% CI 3.8–63.6) and 80.0% (95% CI
37.6–96.4).
FIGURE 4 | PAR incorporation. Marked reduction in PAR was seen in all
patients treated with olaparib-based therapy. Solid line represents patients
treated with olaparib/cediranib and dotted line represents patients treated
with olaparib alone.
Discussion
No validated biomarkers predictive of anti-angiogenic response
have been defined to date. We hypothesized that olaparib and
cediranib in combination would yield greater vascular injury
and clinical activity than olaparib alone in recurrent OvCa. Our
exploratory translational studies suggest that CEC fold change
and IL-8 change on day 3 of treatment may represent biomarkers
predictive for response to the olaparib and cediranib combination.
The presence of CEC has been recognized as a potential
biomarker of vascular damage (19, 35). CEPs have been shown
to infiltrate human tumors and give rise to tumor neovasculature,
whereas mature CECs derive frommature vasculature (36). Thus,
inhibition of the VEGF pathway can attenuate bone marrow-
derived CEPsmobilized by VEGF (37) and can trigger an increase
in circulating mature CECs, reflecting sloughing of fragile mature
endothelium, potentially from tumor vasculature (38, 39). The
number of CECs was reported significantly higher in patients
with metastatic cancer compared with healthy donors (40). Ele-
vated numbers of CEC, reflecting vascular endothelium pertur-
bation by anti-angiogenics, have been described in lymphoma,
and solid tumors including OvCa (18, 19, 35). An increase in
CEC numbers after 6 weeks of treatment correlated with >75%
PSAdecline inmetastatic castrate-resistant prostate cancer treated
with bevacizumab and thalidomide, in addition to docetaxel and
prednisone (35). Our findings support the hypothesis that greater
vascular injury may correlate with clinical response and present
an opportunity to develop a predictive biomarker to this novel
combination.
Most of the inhibitors of angiogenesis are associated with
altered regulation of proangiogenic and proinflammatory
cytokines. Plasma cytokine and angiokine concentrations have
been examined in advanced cancers (32, 41–43). Economopoulou
and colleagues demonstrated that functional γH2AX is required
for cell response to aggravated hypoxia indicating a need for
DNA repair in angiogenesis (9). Thus, it was posited that there
would be greater differences in the pharmacodynamic cytokine
response to the combination of olaparib and cediranib. Our
findings indicate that IL-8 changes correlated with PFS. IL-8
plays an important role in tumor growth and metastasis, and is
associated with tumor burden in melanoma, renal cell cancer,
and hepatocellular carcinoma in vivo models and with worse
prognosis in advanced solid tumors including OvCa (44–46). In
our study, IL-6, circulating VEGF, and soluble VEGFR-2 had no
significant change after treatment and were not different between
two arms, although they have been reported as prognostic
biomarkers in OvCa (47, 48). It is possible that no difference
was observed due to a small sample size and premature sample
collection times to assess the dynamic changes in additional
cytokine biomarkers during treatment. Further studies will be
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FIGURE 5 | DCE-MRI. (A,B) All patients had reduction of Ktrans without
statistically significant differences between arms (p= 0.61). Solid line
represents patients treated with olaparib/cediranib and dot line represents
patients treated with olaparib alone. (C,D) All but one patient had
reduction of Kep after treatment without significant difference between
arms (p= 0.61). Solid line represents patients treated with
olaparib/cediranib and dotted line represents patients treated with
olaparib alone.
needed to consider more comprehensive cytokine panels and
various time points of sample collection.
Incorporation of polyADP ribose moieties at sites of double-
stranded DNA breaks is a signal to the repair machinery to
initiate repair, though it is not a marker of repair per se (49).
It was initially hypothesized that modulation of PAR incor-
poration by PARPi would be both proof of mechanism and
could be used to predict outcome. In our current study, we
prospectively planned to measure PAR incorporation into PBMC
DNA. Proof of mechanism was shown in an early phase 0
study of ABT-888 (veliparib) but we and others have now
shown that this assay in PBMCs does not predict clinical benefit
(25, 49, 50).
Functional tumor imaging with DCE-MRI is capable of eval-
uating changes in vascularity and quality of index lesions (27).
Our results demonstrated vascular flow changes after treatment
but did not correlate with clinical outcome. It has been shown
that the changes of DCE-MRI variables at baseline and at day
28 of cediranib monotherapy were significantly associated with
PFS in metastatic castrate-resistant prostate cancer patients (51).
Chase et al. reported relative blood flow (RBF)measured by DCE-
MRI pre-cycle 1 and pre-cycle 4 of bevacizumab in 13 women
with recurrent OvCa. RBF remained stable for the majority of
the cases (median change  0.21) and was not related to PFS
or OS (34). DCE-MRI may provide early indications of treat-
ment effect even before changes in size can be perceived on CT,
requiring further exploration with optimal sample size and time
points (52).
The combination of olaparib and cediranib has marked clin-
ical activity in women with recurrent platinum-sensitive OvCa.
Our exploratory translational studies suggest that olaparib and
cediranib caused vascular injury and decrease in angiogenesis
indicated by an increase of CEC and decrease in IL-8. These
findings provide insights into the biological effects and represent
potential predictive biomarkers for response to the combina-
tion. Consideration of additional time points and monitoring in
both PBMCs and tissue samples may further improve the overall
clinical utility of these endpoints. Further clinical exploration of
these biomarkers is warranted in patients with OvCa treated with
olaparib and/or cediranib.
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